Tango Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest
Tango Therapeutics, Inc. (TNGX) reported Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest of -$764.60 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Shareholders' Equity
us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest · last filed 2021-08-09
- Tango Therapeutics, Inc. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-06-30 was -$764.60K.
| Period end | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 6 month |
|---|---|---|
| 2021-06-30 | -$764.60K 10-Q · filed 2021-08-09 | -$1.00M 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |